5 completed, 2 active not recruiting, 2 recruiting. 8 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Active not recruiting 2, Recruiting 2 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Dan Zandberg: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC Pembrolizumab, Carboplatin, Paclitaxel - Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | Phase 2 | Recruiting | Dan Zandberg | 15 | 2023-10-03 | 2026-02-09 |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone - Melanoma, NSCLC | Phase 2 | Recruiting | Dan Zandberg | 72 | 2020-09-14 | 2026-06-23 |
| HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma IMRT (Intensity Modulated Radiotherapy), Pembrolizumab, Cisplatin - HPV-Related Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | Dan Zandberg | 18 | 2020-07-06 | 2026-05-13 |
| Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab - Renal Cell Carcinoma, Melanoma | Phase 1 / Phase 2 | Active not recruiting | Dan Zandberg | 70 | 2020-06-11 | 2025-11-06 |
| Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy Nivolumab+Relatlimab, Nivolumab+Ipilimumab - Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Completed | Dan Zandberg | 20 | 2020-05-14 | 2026-01-08 |
| Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer Nivolumab, Relatlimab, Ipilimumab - Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Active not recruiting | Dan Zandberg | 80 | 2019-12-20 | 2026-09-09 |
| Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor - Advanced Solid Tumors, NSCLC | Phase 3 | Completed | Dan Zandberg | 161 | 2019-11-15 | 2025-12-11 |
| Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer Pembrolizumab, Cisplatin, IMRT - Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | Dan Zandberg | 80 | 2016-05-31 | 2024-08-01 |
| Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Reirradiation, MK-3475 - Recurrent Head and Neck Cancer, Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Completed | Dan Zandberg | 48 | 2016-03-09 | 2025-03-06 |
Squamous Cell Carcinoma of Head and Neck (8) · Melanoma (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Squamous Cell (2) · Recurrence (2) · Adenocarcinoma Of Esophagus (1) · Anus Neoplasms (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Head and Neck Neoplasms (1) · Kidney Neoplasms (1)
pembrolizumab (6) · Nivolumab (5) · Ipilimumab (3) · Cisplatin (2) · relatlimab (2) · Carboplatin (1) · Metformin (1) · Opdualag (1) · Paclitaxel (1) · Radiotherapy, Intensity-Modulated (1) · Re-Irradiation (1) · Rosiglitazone (1) · atezolizumab (1) · cemiplimab (1) · spartalizumab (1)
United States (9)
Dan P Zandberg, MD (3) · Dan P Zandberg (1)